BP 1101
Alternative Names: BP-1101Latest Information Update: 05 Oct 2021
At a glance
- Originator BrightPath Biotherapeutics
- Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Oct 2021 BP 1101 is available for licensing as of 05 Oct 2021. https://www.brightpathbio.com
- 01 Oct 2021 Preclinical trials in Cancer in Japan (unspecified route) as of October 2021 (BrightPath Biotherapeutics pipeline; October 2021)